TaiMed Biologics clarified on the 25th that its HIV blockbuster Trogarzo (ibalizumab-uiyk) remains unaffected by recent U.S. tariff policy developments involving President Trump's administration.

• Tariff Status: Following confirmation with manufacturing partner Samsung Biologics, pharmaceuticals exported from South Korea to the U.S. currently maintain 0% tariff status. They are not included in the recently announced "Article 122" measures.
• Legal Context: TaiMed noted that the U.S. Supreme Court recently ruled that the International Emergency Economic Powers Act (IEEPA) does not grant the President the authority to unilaterally impose such tariffs, declaring the measures unlawful.
• Operational Impact: Under Section 232 of the Trade Expansion Act, pharmaceutical products remain exempt. TaiMed confirmed that logistics, customs clearance, and global supply chains remain normal, with no impact on the company’s gross margin structure.

Resource: 中裕：Trogarzo自韓出口美國維持零關稅 未受川普關稅新制影響